Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 62Carcinoma, Non-Small-Cell Lung 45Triple Negative Breast Neoplasms 24Ovarian Neoplasms 20Fallopian Tube Neoplasms 17Neoplasm Metastasis 16Lung Neoplasms 16Endometrial Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Stomach Neoplasms 12Esophageal Neoplasms 10Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Esophageal Squamous Cell Carcinoma 8Colorectal Neoplasms 7Inflammatory Breast Neoplasms 6Head and Neck Neoplasms 6Carcinoma 6Uterine Cervical Neoplasms 5Carcinoma, Ovarian Epithelial 5Melanoma 4Carcinoma, Transitional Cell 4Carcinoma, Squamous Cell 4Adenocarcinoma Of Esophagus 4Urinary Bladder Neoplasms 3Peritoneal Neoplasms 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Lung Diseases 3

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Fallopian Tube Mucinous Adenocarcinoma × Paclitaxel × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡